Cited by 218SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 29 of the 34 references it cites were found in a registry or an index, and 2 are not checked yet.

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Open access

Wang, Kai, Long, Quan-Xin, Deng, Hai-Jun, Hu, Jie, Gao, Qing-Zhu, Zhang, Gui-Ji, He, Chang-Long, Huang, Lu-Yi, Hu, Jie-Li, Chen, Juan, Tang, Ni, Huang, Ai-Long·2021·Clinical Infectious Diseases

DOI 10.1093/cid/ciaa1143PMC PMC7454328

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific neutralizing antibodies (NAbs) in patients with COVID-19. Methods: Blood samples (n = 173) were collected from 30 patients with COVID-19 over a 3-month period after symptom onset and analyzed for SARS-CoV-2–specific NAbs using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines. Results: SARS-CoV-2–specific NAb titers were low for the first 7–10 days after symptom onset and increased after 2–3 weeks. The median peak time for NAbs was 33 days (interquartile range [IQR], 24–59 days) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR, 19.6–42.4%). NAb titers increased over time in parallel with the rise in immunoglobulin G (IgG) antibody levels, correlating well at week 3 (r = 0.41, P < .05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including stem cell factor (SCF), TNF-related apoptosis-inducing ligand (TRAIL), and macrophage colony-stimulating factor (M-CSF). Conclusions: These data provide useful information regarding dynamic changes in NAbs in patients with COVID-19 during the acute and convalescent phases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1143

Cites

29 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Analysis of the plasma response to SARS-CoV-2 infection. A, Sera from 5 convalescent patients with COVID-19 neutralized the SARS-CoV-2 pseudovirus. A serum sample from a healthy individual served as the negative control. The assay was performed in triplicate, and the median percentage of neutralization is shown. B, SARS-CoV-2 NAb titers of 20 plasma samples from convalescent patients with COVID-19 and 10 plasma samples from healthy donors. C, NAbs against VSVG, SARS-CoV, and SARS-CoV-2 pseudovirus in the sera from 30 convalescent patients with COVID-19. Abbreviations: COVID-19, coronavirus disease 2019; F, female; ID50, 50% inhibitory dose; M, male; NAb, neutralizing antibody; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VSVG, vesicular stomatitis virus G.CC BY-NC-ND · PubMed Central

Figure 2. Dynamic changes in NAbs against SARS-CoV-2. A, Kinetics of SARS-CoV-2 NAb levels in 30 patients with COVID-19. B, Number of patients experiencing peak NAb levels during hospitalization or after discharge. Follow-up point 1 represents the follow-up study conducted on 2 April while follow-up point 2 represents the follow-up study conducted on 8 May 2020. C, Peak NAb levels in the patients. D, Comparison of peak NAb levels between patients with COVID-19 experiencing peak NAb levels during hospitalization and patients with COVID-19 experiencing peak NAb levels after discharge. Abbreviations: COVID-19, coronavirus disease 2019; F, female; ID50, 50% inhibitory dose; M, male; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.CC BY-NC-ND · PubMed Central

Figure 3. Decrease in NAb levels in patients with COVID-19. A, Comparison of NAb levels between the peak point and the follow-up time point 2. B, Percentage decrease in NAbs in patients with COVID-19. Abbreviations: COVID-19, coronavirus disease 2019; ID50, 50% inhibitory dose; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.CC BY-NC-ND · PubMed Central

Figure 4. Correlation between the dynamics of NAb and virus-specific IgG levels. A, Kinetics of NAb and IgG levels in 6 patients. Plasma samples were collected at different time points after symptom onset. B, A total of 152 serum samples were grouped by time of collection after symptom onset; correlations were analyzed between NAb levels and IgG levels in each group. C, Correlations between NAb levels and IgG levels from serum samples collected 3 weeks after symptom onset. Abbreviations: F, female; ID50, 50% inhibitory dose; IgG, immunoglobulin G; M, male; NAb, neutralizing antibody.CC BY-NC-ND · PubMed Central

Figure 5. A–C, Correlation between peak NAb levels and cytokines in sera. Serum samples with the highest NAb levels for all individuals were collected during hospitalization. Cytokine or levels were measured using the Bio-Plex Human Cytokine Screening Panel (48-Plex no. 12007283; Bio-Rad) on a Luminex 200 (Luminex Multiplexing Instrument, Merck Millipore), following the manufacturer’s instructions. Pearson’s correlation was used to analyze differences between NAb levels and cytokine levels. Abbreviations: ID50, 50% inhibitory dose; M-CSF, macrophage colony-stimulating factor; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCF, stem cell factor; TRAIL, tumor necrosis factor (TNF)–related apoptosis-inducing ligand.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Self-citation
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citation
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,298
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,968
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes
Connor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038

Show all 34 references

Research works printed but not linked: 1

Luchsinger, 2020, Serological analysis of New York City COVID19 convalescent plasma donors, medRxiv

Sorted by citations

Items 101–200 of 218

Dynamics of infection-elicited SARS-CoV-2 antibodies in children over timePreprint
Gentles, L. E., Kehoe, L., Crawford, K. H. D., Lacombe, K., Dickerson, J. A., Wolf, C. R., Yuan, J., Schuler, S., Watson, J. T., Nyanseor, S., et al. (2022) · medRxiv · doi:10.1101/2022.01.14.22269235 · Cited by 11
Assessing the Quality of Serological Testing in the COVID-19 Pandemic: Results of a European External Quality Assessment (EQA) Scheme for Anti-SARS-CoV-2 Antibody Detection
Ast, V., Costina, V., Eichner, R., Bode, A., Aida, S., Gerhards, C., Thiaucourt, M., Dobler, G., Geilenkeuser, W., Wölfel, R., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00559-21 · Cited by 10
Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine
Peng, P., Deng, H., Hu, J., Wei, X., Xue, J., Li, T., Fang, L., Liu, B., Jin, A., Xu, F.-L., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00311-z · Cited by 11
Self-citation
Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19
Galassi, A., Ciceri, P., Bono, V., Magagnoli, L., Sala, M., Artioli, L., Rovito, R., Hadla, M., Yellenki, V., Monforte, A. D., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10123251 · Cited by 10
Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing
Massachi, J., Donohue, K. C., & Kelly, J. D. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0365 · Cited by 8
Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks
Tanunliong, G., Liu, A. C., Vijh, R., Pidduck, T., Kustra, J., Márquez, A. C., Choi, A., McLennan, M., Hayden, A. S., Kearney, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.775420 · Cited by 10
Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection
Doan, T. A., Forward, T. S., Schafer, J. B., Lucas, E. D., Fleming, I., Uecker-Martin, A., Ayala, E., Guthmiller, J. J., Hesselberth, J. R., Morrison, T. E., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00856-6 · Cited by 9
Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
Martín, M. C., Jimenez, A., Ortega, N., Parrado, A., Page, I., Gonzalez, M., & Blanco-Peris, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264124 · Cited by 9
A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19
Zhang, D., Kukkar, D., Kim, K., & Bhatt, P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129284 · Cited by 6
A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19
Cimolai, N. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00533-4 · Cited by 8
Vaccines against Coronavirus Disease: Target Proteins, Immune Responses, and Status of Ongoing Clinical Trials
Syahniar, R., Purba, M. B., Bekti, H. S., & Mardhia, M. (2020) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.14.4.03 · Cited by 7
Retrospective of International Serological Studies on the Formation and Dynamics of the Humoral Immune Response to SARS-CoV-2: from 2020 to 2021
Novikova, E. A., Петрова, А. Г., Москалева, Е. В., Vanyarkinа, A. S., & Rychkova, L. V. (2021) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2021-6.2.5 · Cited by 9
Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection
Türkkan, A., Saglik, I., Turan, C. A., Sahin, A., Akalin, H., Ener, B., Kara, A., Celebi, S., Sahin, E., & HACIMUSTAFAOĞLU, M. K. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02716-x · Cited by 8
Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review
Kiely, P., Hoad, V. C., Seed, C. R., & Gosbell, I. B. (2022) · Transfusion Medicine and Hemotherapy · doi:10.1159/000522264 · Cited by 8
Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months
Eyran, T., Vaisman‐Mentesh, A., Taussig, D., Dror, Y., Aizik, L., Kigel, A., Rosenstein, S., Bahar, Y., Ini, D., Tur‐Kaspa, R., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010569 · Cited by 8
SARS-CoV-2 infection dynamics in Denmark, February through October 2020: Nature of the past epidemic and how it may develop in the future
Rasmussen, S., Petersen, M. S., & Høiby, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249733 · Cited by 8
Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters
Zhang, C., Guo, Z., Li, N., Cui, H. Y., Meng, K., Liu, L., Zhao, L., Zhang, S., Qin, C., Liu, J., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.722178 · Cited by 8
SARS-CoV-2 epidemiology, antibody dynamics, and neutralisation capacity in Irish healthcare workers in the era of booster COVID-19 vaccinations
McGrath, J., Kenny, C., Nielsen, C. S., Domegan, L. M., Walsh, C., Rooney, P., Walsh, S., Conlon, N. P., Brady, G., Ibrahim, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1078022 · Cited by 7
Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines
Wang, J., Huang, L., Guo, N., Yao, Y., Zhang, C., Xu, R., Jiao, Y., Li, Y.-Q., Song, Y.-R., Wang, F., et al. (2023) · Viruses · doi:10.3390/v15040917 · Cited by 7
Self-citation
SARS-CoV-2 Antibody Testing: Where Are We Now?
Smerczak, E. (2021) · Laboratory Medicine · doi:10.1093/labmed/lmab061 · Cited by 8
Investigation and long‐term monitoring of the presence of neutralizing antibody in patients with COVID‐19 disease of different clinical severity
Kaygusuz, S., Korukluoğlu, G., Coşgun, Y., Şahin, Ö., & Arslan, F. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27751 · Cited by 8
High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralizationPreprint
Noval, M. G., Kaczmarek, M. E., Koide, A., Rodriguez-Rodriguez, B. A., Louie, P., Tada, T., Hattori, T., Panchenko, T., Romero, L. A., Teng, K. W., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.15.252353 · Cited by 7
A longitudinal comparison of spike and nucleocapsid SARS-CoV-2 antibody responses in a tertiary hospital’s laboratory workers with validation of DBS specimen analysisPreprint
Murrell, I., Forde, D., Tyson, L., Chichester, L., Garratt, A., Vineall, O., Palmer, N., Jones, R. E., & Moore, C. (2020) · medRxiv · doi:10.1101/2020.10.29.20219931 · Cited by 7
Severe Acute Respiratory Syndrome Coronavirus‐2
Slev, P. R. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch54 · Cited by 8
Neutralizing Antibody Response by Inactivated SARS-CoV-2 Vaccine on Healthcare Workers
Tandirogang, N., Fitriany, E., Mardania, N., Jannah, M., Dilan, B. F. N., Ratri, S. R., Prakoso, A. D., Aminyoto, M., Ningrum, Y. K., Fikriah, I., et al. (2023) · Molecular and Cellular Biomedical Sciences · doi:10.21705/mcbs.v7i1.303 · Cited by 6
The relationship between IgG and IgM levels and severity of symptoms in COVID-19 patients confirmed by rapid antigen test
AL-Ibraheemi, J. S. S., & AL-Saeedi, A.-S. (2021) · Journal of Medicine and Life · doi:10.25122/jml-2021-0194 · Cited by 6
Hybrid response to SARS-CoV-2 and Neisseria meningitidis C after an OMV-adjuvanted immunization in mice and their offspring
Portilho, A. I., da Costa, H. H. M., Guereschi, M. G., Prudêncio, C. R., & Gaspari, E. D. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2346963 · Cited by 6
Passive Immunity Should and Will Work for COVID-19 for Some Patients
Cimolai, N. (2021) · Clinical Hematology International · doi:10.2991/chi.k.210328.001 · Cited by 7
Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients
Hastert, F. D., Henß, L., von Rhein, C., Gerbeth, J., Wieters, I., Borgans, F., Khodamoradi, Y., Zacharowski, K. D., Rohde, G. G. U., Vehreschild, M. J. G. T., et al. (2022) · Viruses · doi:10.3390/v14050882 · Cited by 6
Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression
Lei, Q., Hou, H., Yu, C., Zhang, Y., Ndzouboukou, J. B., Lin, X., Yao, Z., Fu, H., Ziyong, S., Wang, F., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/9822706 · Cited by 6
Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
Casadevall, A., Joyner, M. J., & Pirofski, L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1213 · Cited by 6
Cytokine and Chemokine Levels in COVID-19 Convalescent Plasma
Bonny, T. S., Patel, E. U., Zhu, X., Grabowski, M., Littlefield, K. E., Laeyendecker, O. B., Casadevall, A., & Tobian, A. A. R. (2020) · Open Forum Infectious Diseases · Cited by 5
Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay
Janaka, S. K., Clark, N. M., Evans, D. T., Mou, H., Farzan, M., & Connor, J. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253551 · Cited by 5
A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays
Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202110702 · Cited by 5
SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study
Brehm, J., Spaeth, A., Dreßler, L., Masetto, T., Dannenberg, R., Peter, C., & Grimmler, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915338 · Cited by 5
Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers
Mouna, L., Razazian, M., Duquesne, S., Roque‐Afonso, A., & Vauloup‐Fellous, C. (2023) · Viruses · doi:10.3390/v15020426 · Cited by 6
Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study
Wang, J., Dong, H., Zhao, J., Li, T., Wang, M., Zhou, C., & Mu, H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1096022 · Cited by 5
Boosting the immunogenicity of the CoronaVac SARS-CoV-2 inactivated vaccine with Huoxiang Suling Shuanghua Decoction: a randomized, double-blind, placebo-controlled study
Tang, R., Wang, L., Zhang, J., Fei, W., Zhang, R., Liu, J., Lv, M., Wang, M., Lv, R., Nan, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1298471 · Cited by 5
The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2
Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5
The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
Tosta, E. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00014 · Cited by 5
Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
Peterhoff, D., Wiegrebe, S., Einhauser, S., Patt, A. J., Beileke, S., Günther, F., Steininger, P. A., Niller, H. H., Burkhardt, R., Küchenhoff, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242536 · Cited by 4
What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 1)
Qaseem, A., Yost, J., Etxeandia‐Ikobaltzeta, I., Forciea, M. A., Abraham, G. M., Miller, M. C., Obley, A. J., & Humphrey, L. L. (2021) · Annals of Internal Medicine · doi:10.7326/m20-7569 · Cited by 4
SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests
Kay, G. A., Owen, S. I., Giorgi, E., Clark, D. J., Williams, C. T., Menzies, S. K., Cuevas, L. E., Davies, B. M. O., Eckersley, N. M., Hughes, G. L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07263-8 · Cited by 4
Recent Advances in Understanding SARS-CoV-2 Infection and Updates on Potential Diagnostic and Therapeutics for COVID-19
Mukherjee, M. D., Kumar, A., Solanki, P. R., Verma, D., Yadav, A. K., Chaudhary, N., & Kumar, P. (2022) · Coronaviruses · doi:10.2174/2666796703666220302143102 · Cited by 4
Broad Spectrum Antiviral Therapy can Supersede Vaccination Strategy for Combating COVID-19 Pandemic
Chakraborty, A. K. (2021) · Medical Journal of Clinical Trials & Case Studies · doi:10.23880/mjccs-16000298 · Cited by 3
Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome
Gerhards, C., Kittel, M., Ast, V., Bugert, P., Froelich, M. F., Hetjens, M., Haselmann, V., Neumaier, M., & Thiaucourt, M. (2023) · Viruses · doi:10.3390/v15020454 · Cited by 4
Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity—lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices
McGrath, J., O’Doherty, L., Conlon, N. P., Dunne, J., Brady, G., Ibrahim, A., McCormack, W. J., Walsh, C., Domegan, L. M., Walsh, S., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1245464 · Cited by 4
Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020
Yuan, Y., Yu, L., Jin, Z., Wang, Y., Gao, M. Q., Ding, H., Zhuo, X., Zhu, X. M., Gao, F., Zheng, X., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.650487 · Cited by 4
What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2)
Qaseem, A., Yost, J., Etxeandia‐Ikobaltzeta, I., Forciea, M. A., Abraham, G. M., Miller, M. C., Obley, A. J., Humphrey, L. L., Akl, E. A., Andrews, R., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-3272 · Cited by 4
Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma UnitsPreprint
Janaka, S. K., Hartman, W. R., Mou, H., Farzan, M., Stramer, S. L., Goodhue, E., Weiss, J., Evans, D. T., & Connor, J. P. (2021) · medRxiv · doi:10.1101/2021.02.25.21252463 · Cited by 4
Shielding under endemic SARS-CoV-2 conditions is easier said than done: a model-based analysisPreprint
Stoddard, M., Lin, Y., Sarkar, S., Mazewski, M., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., et al. (2023) · medRxiv · doi:10.1101/2023.01.22.23284884 · Cited by 3
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Responses After Community Infections in Children and Adults
Dawood, F. S., Couture, A., Zhang, X., Stockwell, M. S., Porucznik, C. A., Stanford, J. B., Hetrich, M. K., Veguilla, V., Thornburg, N. J., Heaney, C. D., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad168 · Cited by 3
Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023
Zhang, H., Li, B., Sun, J., Zou, L., Yi, L., Lin, H., Zhou, P., Liang, C., Zeng, L., Zhuang, X., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02573-x · Cited by 3
Immune response and safety of inactivated SARS-CoV-2 vaccines during pregnancy: a real-world observational study
Gong, Y., Zhang, X., Han, X., Chen, B., Xu, Y., Huang, J., Yang, W., Fu, X., Wang, Q., Li, Z., et al. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2272655 · Cited by 3
Nanomaterial‐Based Optical Biosensors for SARS‐CoV‐2 Detection: A Retrospective of the Pandemic
Martin, F., Harroun, S. G., & Meunier, M. (2025) · Advanced Sensor Research · doi:10.1002/adsr.202400188 · Cited by 3
Особенности гуморального иммунного ответа при коронавирусной болезни (COVID-19)
Зінчук, О. М., Petrukh, A. V., Hrynchyshyn, N. I., & Shvaievska, К. К. (2021) · ACTUAL INFECTOLOGY · doi:10.22141/2312-413x.9.1.2021.228825 · Cited by 3
SARS-CoV-2 RT-PCR positivity of individuals subsequent to completing quarantine upon entry into a country during a transmission-free period
Srichatrapimuk, S., Chookajorn, T., Kochakarn, T., Kirdlarp, S., Pasomsub, E., Chantratita, W., Iamsirithaworn, S., Kunakorn, M., Thitithanyanont, A., D, S. S. M., et al. (2022) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2022.102271 · Cited by 3
Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
Liu, W.-D., Hung, C., Wang, J., Tsai, M.-J., Kuo, P.-H., Chao, T., Hsieh, S., Sheng, W., Chen, Y., Chang, S., et al. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.04.010 · Cited by 3
Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019
Bainbridge, E. D., Hsue, P. Y., Esensten, J. H., Lynch, K. L., Hendrickson, C. M., Doernberg, S. B., Fung, M., Chin-Hong, P. V., Germanio, C. D., Norris, P. J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab385 · Cited by 3
Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and UtilityPreprint
Tedder, R. S., Parker, E. L., Sureda-Vives, M., Fernández, N., Randell, P. A., Marchesin, F., Katsanovskaja, K., Harvey, R., Lilley, A., Harris, B. H. L., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3739821 · Cited by 3
The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis
Stoddard, M., Yuan, L., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2025) · Vaccines · doi:10.3390/vaccines13040368 · Cited by 8
Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients
Poolchanuan, P., Matsee, W., Dulsuk, A., Phunpang, R., Runcharoen, C., Boonprakob, T., Hemtong, O., Chowplijit, S., Chuapaknam, V., Siripoon, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-98627-3 · Cited by 2
Dynamics of humoral immune response in SARS-CoV-2 infected individuals with different clinical stages
Cortina, Y. A. M., Rodríguez-Perea, A. L., Chvatal‐Medina, M., Lopera, T. J., Mesa, N. Á., Rodas-Marín, J. K., Moncada, D. C., Rugeles, M. T., & Velilla, P. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007068 · Cited by 2
BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs
Rahman, M. A., Goldfarbmuren, K., Sarkis, S., Bissa, M., Gutowska, A., Schifanella, L., Moles, R., Doster, M., Andersen, H., Jethmalani, Y., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.194633 · Cited by 2
Realization of humoral immunity against SARS-CoV-2 infections
Lin, Y., Zhao, Z., Zheng, J., Liu, J., & Huang, A. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.008 · Cited by 2
Self-citation
Four Distinct Cases of Multisystem Inflammatory Syndrome in Adults Associated With SARS-CoV-2 Infection at a Community Hospital in New Jersey
Vyas, C., Dalmacion, D. L. V., Almeligy, A., Juan, R., Pernia, J., Obaid, A., Heis, F., Patel, S., Eng, M., Patton, C. D., et al. (2021) · Cureus · doi:10.7759/cureus.20651 · Cited by 2
Isotyping and quantitation of the humoral immune response to SARS-CoV-2
Goyins, K. A., Yu, J., Papp, S. B., Beddard, R. L., Murthy, A. K., Chambers, J. P., & Arulanandam, B. P. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221084966 · Cited by 3
Two-years antibody responses following SARS-CoV-2 infection in humans: A study protocol
Arguni, E., Dewi, F. S. T., Fachiroh, J., Paramita, D. K., Lestari, S. K., Wiratama, B. S., Susilaningrum, A. R., Kharisma, B., Meisyarah, Y. H., Sari, M. P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272690 · Cited by 2
Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus
Shang, Y., Liu, T., Li, J., Kaweme, N. M., Wang, X., & Zhou, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.580147 · Cited by 2
Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans
Watson, M. E., Inagaki, K., & Weinberg, J. B. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-21-000011 · Cited by 3
Impact of Prior Infection on Protection and Transmission of SARS-CoV-2 in Golden HamstersPreprint
Zhang, C., Guo, Z., Li, N., Cui, H. Y., Meng, K., Liu, L., Zhao, L., Zhang, S., Qin, C., Liu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.30.428920 · Cited by 2
Vaccine-induced immune responses against SARS-CoV-2 infections
Garg, M. K., Maralakunte, M., Kumar, Y., Bhujade, H., Sehgal, I. P., Suri, V., & Garg, S. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00024 · Cited by 1
Humoral Immune Response in SARS-CoV-2 Infection and Its Therapeutic Relevance
Correa, V. A., Portilho, A. I., Gaspar, E. B., & Gaspari, E. D. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_2 · Cited by 1
Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy
Coşan, F., Demirel, Ö. Ü., Yalcin, D., SONKAYA, M. M., ULUIŞIK, I. E., Cecen, O., Furuncuoğlu, Y., Çelikmen, D. S. M., Kara, O., Ceylan, E., et al. (2023) · BMC Rheumatology · doi:10.1186/s41927-023-00342-x · Cited by 1
SARS-CoV-2 Antibody Kinetics in Unvaccinated Hospitalized Children With COVID-19
Dimopoulou, D., Charakida, M., Marmarinos, A., Karaviti, D., Avgeris, M., Gourgiotis, D., & Tsolia, M. N. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004301 · Cited by 1
A tentative exploration for the association between influenza virus infection and SARS-CoV-2 infection in Shihezi, China: A test-negative study
Xie, S., Su, Y., Zhao, Y., Du, Y., Guo, Z., Gu, X., Sun, J., Javanbakht, M., He, D., Zhang, J., et al. (2024) · Infectious Disease Modelling · doi:10.1016/j.idm.2024.10.002 · Cited by 1
Self-citation
Catch those antibodies before they fall
Shaz, B. H., & Cohn, C. S. (2020) · Blood · doi:10.1182/blood.2020008768 · Cited by 1
Inmunidad y vacunación contra la covid-19
Anaya, J., González, J. M., Villalba-Vizcaíno, V., Grajales, P. J. P., Rengifo, C., Trillos, C., & Gamboa, L. F. (2021) · Medicina · doi:10.56050/01205498.1558 · Cited by 1
Profiling of SARS‐CoV‐2 neutralizing antibody‐associated antigenic peptides signature using proteome microarray
Wu, M., Liu, J., Wang, X., Zhang, X., Liang, T., Chen, L., Huang, T., Li, Y., Zheng, C. J., Yang, Y., et al. (2023) · MedComm · doi:10.1002/mco2.361 · Cited by 1
Serological survey of SARS-CoV-2 incidence conducted at a rural West Virginia hospitalPreprint
Horspool, A. M., Russ, B. P., Wolf, M. A., Kang, J. H., Blackwood, C. B., Hall, J. M., Wong, T. Y., DeJong, M. A., Bitzer, G. J., Bevere, J. R., et al. (2021) · medRxiv · doi:10.1101/2021.08.16.21262128 · Cited by 1
SARS-COV-2 Neutralizing Activity in Serum Collected from Recovered and Vaccinated Health Care WorkersPreprint
Mouna, L., Razazian, M., Duquesne, S., Roque-Afonso, R.-A., & Vauloup‐Fellous, C. (2021) · Research Square · doi:10.21203/rs.3.rs-951588/v1 · Cited by 1
Antibody Dependent Enhancement (ADE) of Infection into Macrophages Validates the Importance of HERV-K102 Particle Production for Pandemic PreparednessPreprint
Laderoute, M. P. (2023) · Preprints.org · doi:10.20944/preprints202312.0185.v1
Antibody Dependent Enhancement (ADE) of Infection into Macrophages Validates the Importance of HERV-K102 Particle Production for Pandemic PreparednessPreprint
Laderoute, M. P. (2024) · Preprints.org · doi:10.20944/preprints202312.0185.v2
The Frequency of SARS-CoV-2 Specific Memory B Cells in COVID-19 Recovered Patients Remain Stable While Antibodies Decay Over TimePreprint
Vaisman‐Mentesh, A., Dror, Y., Maimon, L., Kigel, A., Rosenstein, S., Eyran, T., Bahar, Y., Taussig, D. C., Tur‐Kaspa, R., Kournos, T., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3751788
Immunoglobulin-G Enzyme-Linked Immunosorbent Assay Predicts Neutralising Antibody Response in Convalescent SARS-CoV-2 PatientsPreprint
Kay, G. A., Owen, S. I., Giorgi, E., Williams, C. T., Menzies, S. K., Clark, D. J., Cuevas, L. E., Davies, B. M. O., Eckersley, N. M., Hughes, G. L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-329341/v1
КОРОНАВІРУСНА ХВОРОБА(COVID-19). ВИКЛИКИ ТА ПЕРСПЕКТИВИ СПЕЦИФІЧНОЇ ДІАГНОСТИКИ
Gumeniuk, K., Дубина, Д., & Юрченко, О. О. (2021) · Microbiology&Biotechnology · doi:10.18524/2307-4663.2021.1(51).226901
Characterization of Specific Humoral Immunity in Asymptomatic SARS-CoV-2 Infection
Deng, Y., Zheng, J., Lin, Y., & Huang, A. (2021) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000024
Self-citation
Severe Acute Respiratory Syndrome Coronavirus 2 Serology Testing – A Laboratory Primer
Slev, P. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.003
Probability of Resurgence and Scale of Transmission of COVID-19 in China Depend on Passive Case Detection CapacityPreprint
Pan, J., Liu, Z., Wang, X., Yao, Y., & Wang, W. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3975357
Additional Doses of Vaccines against COVID-19 - Attempting to Enhance the Immune Response
Alvez, F. (2022) · doi:10.36959/669/748
Determination of IgG and IgM against COVID- 19 for Recovered Patients at Different Intervals and by Different Techniques
Al-Hadidi, E. W., & Altobje, M. A. (2022) · Journal of Life and Bio Sciences Research · doi:10.38094/jlbsr30152
The SARS-CoV-2 RNA with mild lung lesions lasts longer in non-severe COVID-19 patients: a case series studyPreprint
Zhang, C., Li, J., Mu, J., Zhang, D., Wang, H., Jin, Y., Han, Y., Li, H., Zhang, C., Yu, P., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-43643/v1
Antibody Response to SARS-CoV-2 Infection in Non Vaccinated Health Care Personnel
Khanam, P. A., Hassan, M. S., Alam, M. S., Belal, M. H., Rahman, Z. F., Begum, T., & Khan, A. (2022) · Journal of Bangladesh College of Physicians and Surgeons · doi:10.3329/jbcps.v40i3.60303
Maternal Antibody Response and Transplacental Transfer Following SARS-CoV-2 Infection or Vaccination in PregnancyPreprint
Otero, S., Miller, E. S., Sunderraj, A., Shanes, E. D., Sakowicz, A., Goldstein, J. A., & Mithal, L. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4060082
Longitudinal Assessment of Anti-Spike-1 antibody Responses in a Group of Hospitalized Patients with SARS-CoV-2 Infection
Özdede, M., Uyaroğlu, O. A., Tanrıöver, M. D., Guven, G. S., Şener, B., & Zarakolu, P. (2022) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20229714
"SARS-CoV-2 Antibodies and Immunity: Still to Explore for COVID-19"
Chakraborty, A. K. (2022) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2022.45.007229
D614G SARS-CoV-2 Pseudovirus Infectivity and Binding of Spike Protein to the ACE2 Receptor Inversely Correlates with Serum SARS-CoV-2-Specific IgG Levels
McCullagh, L., Sheehy, N., Gascun, C. F. D., & Hassan, J. (2023) · Viral Immunology · doi:10.1089/vim.2022.0117
Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country
Sayabovorn, N., Phisalprapa, P., Srivanichakorn, W., Chaisathaphol, T., Washirasaksiri, C., Sitasuwan, T., Tinmanee, R., Kositamongkol, C., Nimitpunya, P., Mepramoon, E., et al. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8040185
Comparison of Neutralizing Sars Cov-2 Igg Antibody Levels in Hospitalized Patients at Dr. Mohammad Hoesin Palembang Hospital
Ahmad, Z., Sudarto, S., Linda, R., Pasaribu, R. P., Alif, F. R., Rasyidi, S., & Liana, P. (2023) · Malahayati Nursing Journal · doi:10.33024/mnj.v5i5.8515
Determining clinical biomarkers to predict long-term SARS-CoV-2 antibody response among COVID-19 patients in Bangladesh
Ahmed, T., Hasan, S. M. T., Akter, A., Tauheed, I., Akhtar, M., Rahman, S. I. A., Bhuiyan, T. R., Ahmed, T., Qadri, F., & Chowdhury, F. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1111037

Authors: Wang, K., Long, Q.-X., Deng, H.-J., Hu, J., Gao, Q.-Z., Zhang, G.-J., He, C.-L., Huang, L.-Y., Hu, J.-L., Chen, J., Tang, N., & Huang, A.-L.
Affiliations: Second Affiliated Hospital of Chongqing Medical University (CN)
Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Corresponding author: Huang, Ai-Long
ORCID: Wang, Kai
Hu, Jie
Chen, Juan
Tang, Ni
Huang, Ai-Long
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2020-08-03
Volume: 73
Issue: 3
Pages: e531-e539
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1093/cid/ciaa1143
PMC: PMC7454328
OpenAlex: W3046309975
Cited by: 218
References: 34
Citations by year: 2026: 1 · 2025: 8 · 2024: 15 · 2023: 26 · 2022: 37 · 2021: 101 · 2020: 30
FWCI: 6.36
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Science and Technology Commission of Chongqing (cstc2020jscx-fyzx0053)
Chongqing Medical University (CQMUNCP0302, CQMUNCP0304)
Leading Talent Program of Chongqing Science and Technology Commission (CSTCCXLJRC201719)
Major National Science and Technology Program (2017ZX10202203)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, antibody kinetics, IgG, inflammatory cytokines, stem cell factor, TRAIL, macrophage colony-stimulating factor, convalescence
MeSH terms: COVID-19, SARS-CoV-2, Antibodies, Viral, Humans, Antibodies, Neutralizing, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks